May 09, 2017
Boulder, CO – May 09, 2017 – Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become Chairman of Muse bio’s Board of Directors. In addition to Illumina, Dr. Stuelpnagel has co-founded and held senior leadership roles in several life science companies and brings extensive knowledge in building successful enterprises and commercializing disruptive technologies.
February 28, 2017
Boulder CO – February 28, 2017 - Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.
December 15, 2016
Boulder, CO – December 15, 2016 – Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision.
December 7, 2016
Boulder CO - December 7, 2016 - Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors.